Genetic process for the preparation of antibiotic-producer
micromonospora strains
    1.
    发明授权
    Genetic process for the preparation of antibiotic-producer micromonospora strains 失效
    用于制备抗生素 - 微生物菌株的遗传过程

    公开(公告)号:US4294927A

    公开(公告)日:1981-10-13

    申请号:US92554

    申请日:1979-11-08

    IPC分类号: C12N15/03 C12N15/00

    摘要: The invention provides a process for the preparation of antibiotic-producer Micromonospora strains having modified genetic material, wherein a protoplast suspension is prepared with lysozyme, under osmotically buffered conditions ensured by sucose, from each culture of the two genetically marked mutants of the antibiotic-producer Micromonospora strain following cultivation in a glycine medium, both suspensions obtained are combined in the presence of polyethylene glycol, and incubated at room temperature, the resulting fused protoplasts are suspended in soft agar, then plated on an agar plate containing sucrose, prolin and inorganic salts, incubated for 20 to 30 days, and finally all mutants are selected from the regenerated colonies which are sure to have genetic material different from that of the parent strains.The process can be advantageously applied to improve productivity of antibiotic-producer strains having industrial importance.

    摘要翻译: 本发明提供了一种用于制备具有修饰遗传物质的抗生素 - 生产物单孢菌菌株的方法,其中在抗生素生产者的两个遗传标记的突变体的每个培养物中,在通过sucose保证的渗透缓冲条件下,用溶菌酶制备原生质体悬浮液 在甘氨酸培养基中培养后的微单孢菌菌株,将得到的两种悬浮液在聚乙二醇存在下合并,并在室温下温育,将得到的融合原生质体悬浮在软琼脂中,然后铺在含有蔗糖,脯氨酸和无机盐 ,孵育20至30天,最后所有突变体选自再生菌落,其确保具有与亲本菌株不同的遗传物质。 该方法可以有利地应用于提高具有工业重要性的抗生素 - 生产菌株的生产力。

    Human cytomegalovirus DNA constructs and uses therefor
    2.
    发明授权
    Human cytomegalovirus DNA constructs and uses therefor 有权
    人巨细胞病毒DNA构建体及其用途

    公开(公告)号:US06448389B1

    公开(公告)日:2002-09-10

    申请号:US09171699

    申请日:1999-01-19

    IPC分类号: C07H2104

    摘要: Novel DNA molecules for in vitro and in vivo expression of HCMV gB, gB transmembrane deleted derivatives, pp65, pp150, and IE-exon-4 proteins are described. Preferably, the molecules are plasmids. Also described are methods of using these DNA molecules to induce immune responses to HCMV, and the use of a plasmid of the invention to prime immune responses to HCMV vaccines.

    摘要翻译: 描述了用于体外和体内表达HCMV gB,gB跨膜缺失衍生物,pp65,pp150和IE-外显子-4蛋白的新型DNA分子。 优选地,分子是质粒。 还描述了使用这些DNA分子诱导对HCMV的免疫应答的方法,以及使用本发明的质粒来引发对HCMV疫苗的免疫应答。

    Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies
    3.
    发明授权
    Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies 有权
    开发掩蔽的治疗性抗体以限制脱靶效应; 应用于抗EGFR抗体

    公开(公告)号:US08895702B2

    公开(公告)日:2014-11-25

    申请号:US13542805

    申请日:2012-07-06

    IPC分类号: C07K16/28 C07K16/00 C07K16/30

    摘要: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.

    摘要翻译: 在一个实施方案中,提供了掩蔽的单克隆抗体(mAb),由核酸序列或包含信号序列,掩蔽表位序列的氨基酸序列分子编码的mAb,可通过蛋白酶特异性的蛋白酶切割的接头序列 目标组织; 和抗体或其功能片段。 在另一个实施方案中,提供了跨屏蔽的mAb异二聚体复合物,其包含第一掩蔽的mAb,其包含第一信号序列,第一掩蔽表位序列,可被靶组织特异性的蛋白酶切割的第一接头, 抗体或其片段; 和第二掩蔽的mAb,其包含第二信号序列,第二掩蔽表位序列,可被靶组织特异性的蛋白酶切割的第二接头和第二抗体或其片段。

    DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES
    4.
    发明申请
    DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS: APPLICATION TO ANTI-EGFR ANTIBODIES 审中-公开
    掩蔽性治疗抗体的开发限制非靶标效应:应用于抗EGFR抗体

    公开(公告)号:US20110178279A1

    公开(公告)日:2011-07-21

    申请号:US12849786

    申请日:2010-08-03

    IPC分类号: C07K16/28 C07K16/00 C07H21/04

    摘要: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.

    摘要翻译: 在一个实施方案中,提供了掩蔽的单克隆抗体(mAb),由核酸序列或包含信号序列,掩蔽表位序列的氨基酸序列分子编码的mAb,可通过蛋白酶特异性的蛋白酶切割的接头序列 目标组织; 和抗体或其功能片段。 在另一个实施方案中,提供了跨屏蔽的mAb异二聚体复合物,其包含第一掩蔽的mAb,其包含第一信号序列,第一掩蔽表位序列,可被靶组织特异性的蛋白酶切割的第一接头, 抗体或其片段; 和第二掩蔽的mAb,其包含第二信号序列,第二掩蔽表位序列,可被靶组织特异性的蛋白酶切割的第二接头和第二抗体或其片段。

    DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS; APPLICATION TO ANTI-EGFR ANTIBODIES
    5.
    发明申请
    DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS; APPLICATION TO ANTI-EGFR ANTIBODIES 有权
    掩蔽性治疗抗体的设计和开发限制非目标效应; 应用于抗EGFR抗体

    公开(公告)号:US20130150558A1

    公开(公告)日:2013-06-13

    申请号:US13542805

    申请日:2012-07-06

    IPC分类号: C07K16/28

    摘要: In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a cross-masked mAb heterodimer complex is provided, comprising a first masked mAb, comprising a first signal sequence, a first masking epitope sequence, a first linker that is cleavable by a protease specific to a target tissue, and a first antibody or fragment thereof; and a second masked mAb, comprising a second signal sequence, a second masking epitope sequence, a second linker that is cleavable by a protease specific to a target tissue, and a second antibody or fragment thereof.

    摘要翻译: 在一个实施方案中,提供了掩蔽的单克隆抗体(mAb),由核酸序列或包含信号序列,掩蔽表位序列的氨基酸序列分子编码的mAb,可通过蛋白酶特异性的蛋白酶切割的接头序列 目标组织; 和抗体或其功能片段。 在另一个实施方案中,提供了跨屏蔽的mAb异二聚体复合物,其包含第一掩蔽的mAb,其包含第一信号序列,第一掩蔽表位序列,可被靶组织特异性的蛋白酶切割的第一接头, 抗体或其片段; 和第二掩蔽的mAb,其包含第二信号序列,第二掩蔽表位序列,可被靶组织特异性的蛋白酶切割的第二接头和第二抗体或其片段。